FRI0029 Clinical significance of 14–3–3eta protein levels in patients with rheumatoid arthritis

Abstract

Background14–3–3η is a protein that is overexpressed in serum and joint fluid of patients with rheumatoid arthritis (RA) and may represent a diagnostic biomarker for RA.ObjectivesWe assessed the prevalence and serum levels of 14–3–3η in patients with RA and with other rheumatic diseases.MethodsSerum levels of 14–3–3η were measured in 96 patients with RA, in 101 patients with other rheumatic diseases and in 66 healthy subjects. The RA group consisted of 51 patients with well-established RA who were treated with different DMARDs, and 45 patients with early untreated disease (onset of less than 1 year). The disease control group included 33 patients with systemic lupus erythematosus (SLE), 44 patients with ankylosing spondylitis (AS) and 24 psoriatic arthritis (PsA) patients. All of the sera samples were evaluated by JOINT stat 14–3–3η ELISA test kits (Augurex Life Sciences Corp.). The cut-off was defined as 0.19 ng/ml.ResultsMedian (IQR) 14–3–3η levels were significantly higher in the early RA group [0.25 ng/ml (0.075–3.11)] and in established RA patients [0.15 ng/ml (0.08–1.26)] in comparison with healthy subjects [0 ng/ml (0–0)] and disease controls: SLE [0.01 ng/ml (0–0.055)], AS [0.05 ng/ml (0–0.255)] and PsA [0.01 ng/ml (0–0.065)].The prevalence of 14–3–3η positivity in early RA patients was 58%, significantly higher than in the disease control group (SLE: 9%, p<0.001; AS: 27%, p<0.002, PsA: 12.5%, p<0.001) and in the healthy subjects group (5%, p<0.001). In established-RA patients, this prevalence was 43%, and it was significantly higher than in disease control and healthy subjects groups (p<0.05), excluding the AS group (p=0.054).ConclusionsThe concentration of 14–3–3η protein may be used to distinguish between patients with early RA and patients with other rheumatic diseases and serve as an additional biomarker in the diagnosis of RA.Disclosure of InterestO. Shovman: None declared, B. Gilburd: None declared, A. Watad: None declared, H. Amital: None declared, P. Langevitz: None declared, N. L. Bragazzi: None declared, M. Adawi: None declared, D. Pérez: None declared, G. Bornstein : None declared, M. Lidar : None declared, M. Blank: None declared, Y. Azuri: None declared, N. K. Biln Employee of: Augurex Life Sciences Corp, A. Marotta Employee of: Augurex Life Sciences Corp, Y. Shoenfeld: None declared

The association among 14-3-3η protein, inflammation, bone remodeling and osteoporosis in patients with rheumatoid arthritis

“…The positivity of 14-3-3η was defined as ≥0.19 ng/ml according to the manufacturer’s recommended cutoff. 3 I-CTX and PINP were measured using automatic electrochemical luminescence immune-analyzer 7 .…”

“…6 The positivity of 14-3-3η was defined as ≥0.19 ng/ml according to the manufacturer's recommended cutoff. 3 I-CTX and PINP were measured using automatic electrochemical luminescence immune-analyzer. 7 Statistical analysis: Statistical analysis was performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).…”

“…2 14-3-3η proteins, a family of molecular chaperons, play an important role in the regulation of intracellular functions including proliferation, differentiation, metabolism, and many others. 3 Among the proteins, the 14-3-3η protein has been regarded as a described and validated biomarker that has both a diagnostic and a prognostic value in RA. 1 Moreover, in a study carried out by Gong, the level of serum 14-3-3η protein was found to be negatively correlated with bone mineral density (BMD) in RA patients, and serum 14-3-3η protein among groups of normal bone mass, osteopenia, and osteoporosis was significantly different, demonstrating 14-3-3η protein may affect the progression of osteoporosis in RA patients.…”